Concizumab plasma concentrations
| . | explorer4 . | explorer5 . | |||
|---|---|---|---|---|---|
| Concizumab dose, mg/kg | 0.15 | 0.20 | 0.15 | 0.20 | 0.25 |
| N | 15 | 2 | 18 | 4 | 6 |
| Mean, ng/mL (SD) | 350.6 (316.8) | 517.5 (309.0) | 195.2 (147.0) | 374.4 (644.0) | 2640.8 (4085.6) |
| CV (%) | 90.4 | 60.0 | 75.3 | 172.0 | 154.7 |
| Min; max | 85.8; 1126 | 299; 736 | 66.5; 538 | 26.9; 1340 | 280; 10 794 |
| . | explorer4 . | explorer5 . | |||
|---|---|---|---|---|---|
| Concizumab dose, mg/kg | 0.15 | 0.20 | 0.15 | 0.20 | 0.25 |
| N | 15 | 2 | 18 | 4 | 6 |
| Mean, ng/mL (SD) | 350.6 (316.8) | 517.5 (309.0) | 195.2 (147.0) | 374.4 (644.0) | 2640.8 (4085.6) |
| CV (%) | 90.4 | 60.0 | 75.3 | 172.0 | 154.7 |
| Min; max | 85.8; 1126 | 299; 736 | 66.5; 538 | 26.9; 1340 | 280; 10 794 |
Concizumab plasma concentrations (nanograms per milliliter) prior to the last dose administration at 24 weeks in explorer4 (HAwI/HBwI) and explorer5 (HA without inhibitors), at each dose level.
CV, coefficient of variation. See Table 1 for expansion of other abbreviations.